40 results about "Tocopherol polyethylene glycol succinate" patented technology

A powdered tocopheryl polyethylene glycol succinate (TPGS™) having an average particle size of less than about 1000 microns. In one embodiment, the powdered tocopheryl polyethylene glycol succinate is prepared by a process that includes atomizing a fluidic tocopheryl polyethylene glycol succinate into an environment suitable for solidifying the atomized tocopheryl polyethylene glycol succinate. In another embodiment, the powdered tocopheryl polyethylene glycol succinate is prepared by a process of applying a force to a solid tocopheryl polyethylene glycol succinate starting material that is sufficient to produce a powdered product.

A liquid comprising a therapeutically effective concentration of a cyclosporin and a vitamin E tocopherol polyethylene glycol succinate, wherein said liquid is an aqueous solution, and wherein no hydrophilic organic solvent is present at a concentration greater than half of that of the cyclosporin is also disclosed herein. A composition comprising a therapeutically effective concentration of cyclosporin A and an effective amount of a vitamin E tocopherol polyethylene glycol succinate, wherein said composition is an aqueous liquid solution which is intended for ophthalmic use, and wherein no hydrophilic organic solvent is present at a mass concentration greater than or equal to that of the cyclosporin, is disclosed herein. A composition comprising a therapeutically effective concentration of cyclosporin A and an effective amount of a vitamin E tocopherol polyethylene glycol succinate, wherein said composition is an aqueous liquid solution which is intended for parenteral use, and wherein no hydrophilic organic solvent is present at a mass concentration greater than or equal to that of the cyclosporin, is disclosed herein. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.

Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and α-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.

Pharmaceutical formulations comprising cabazitaxel, solubilizer, tocopherol polyethylene glycol succinate (TPGS), one or more hydrotropes, optionally one or more agents having a pK_a of about 3 to about 6, and optionally one or more antioxidizing agents, wherein the formulations are substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol or ethanol. Pharmaceutical formulations may alternatively comprise cabazitaxel, solubilizer, optionally one or more agents having a pK_a of about 3 to about 6, and optionally one or more antioxidizing agents, wherein the formulations are substantially free of polysorbates and polyethoxylated castor oil. These formulations may be combined with a diluent, which comprises TPGS and one or more hydrotropes. Methods of administering the cabazitaxel formulations include combining the formulations with an infusion solution.

A liquid comprising a therapeutically effective concentration of a cyclosporin and a vitamin E tocopherol polyethylene glycol succinate, wherein said liquid is an emulsion. is disclosed herein. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.

The invention discloses a paclitaxel mixed micelle preparation, comprising 100 to 300 milligram of tocopherol polyethylene glycol succinate 1000 (TPGS), 0 to 50 milligram of phosphatide, 0.5 milliliter of anhydrous ethanol and 6 milligram of paclitaxel. The preparation method is as follows: the TPGS is dissolved in the anhydrous ethanol, or the TPGS and the phosphatide are dissolved in the anhydrous ethanol; the paclitaxel is added and dissolved under stirring; the mixture is filtered with a millipore filtration of 0.22 micrometer so as to obtain the paclitaxel mixed micelle preparation. In the invention, the TPGS and the phosphatide are used to form mixed micelles which have good stability and little toxic and side effects; the preparation method is simple and practicable, having a good application prospect. Compared to the prior art, polyoxyethylene castor oil in conventional prescription is substituted in the invention, thereby reducing toxic side effects of paclitaxel injections and greatly enhancing the safety of the injections on condition that solubility is guaranteed.

The invention relates to the field of Chinese medicine preparation, in particular to a method for preparing tripterine nano structure lipid carrier containing traditional Chinese medicine monomer and application of the tripterine nano structure lipid carrier in preparation of transdermal drugs used for treating psoriasis, rheumatoid arthritis, skin cancer and breast cancer. The tripterine nano structure lipid carrier is characterized by comprising the following components in parts by weight: 1 part of tripterine, 5-100 parts of mixed lipid, 0.5-10 parts of phospholipid, 0.1-15 parts of poloxamer-188 and 0.5-10 parts of vitamin E and tocopherol polyethylene glycol succinate, wherein the mixed lipid is composed of solid lipid monoglycerine and liquid lipid octylic acid/caprin according to the weight ratio of 1: 0.1-10: 1. Tripterine is prepared into the nano structure lipid carrier, the tripterine nano structure lipid carrier in a semi-solid or liquid preparation form is applied in a transdermal way, bioavailability of the tripterine can be improved, toxic response of tripterine can be reduced, and the nano structure lipid carrier provided by the invention has great clinical application value in the improvement of the treatment effect of tripterine.

The present invention relates to a TPGS article having a weight no greater than 1 gram and a tackiness no greater than about 1550 grams. In addition, the present invention relates to a process for producing said TPGS articles.

The invention provides cabazitaxel long-circulation liposome injection and a preparation method thereof. The cabazitaxel long-circulation liposome injection comprises cabazitaxel or a pharmaceutically acceptable salt thereof, tocopherol polyethylene glycol succinate, distearoyl-phosphatidylethanolamine-polyethylene glycol-maleimide and phospholipid. The cabazitaxel long-circulation liposome injection is prepared by a film method. The liposome not only has the advantages of reduced toxicity, simple and convenient clinical use and improved bioavailability, but also has good stability of storage and use.

A pharmaceutical composition comprising:

• (a) a medium system, comprising a first component, a second component and a third component, wherein the first component is a phosphate buffered saline, the second component is selected from the group consisting of vegetable oils, animal oils, fatty acids and combinations thereof, and the third component is selected from the group consisting of polyethylene glycol, dimethyl sulfoxide (DMSO), ethanol, polypropylene glycol, polysorbate, polyoxyethylated vegetable oil, ethyl acetate, 2-hydroxyethyl 12-hydroxyoctadecanoate, tocopheryl polyethylene glycol succinate and combinations thereof; and
• (b) n-butylidenephthalide (BP).

Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and α-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.

The invention discloses a hydroxycamptothecine long-circulating liposome and a preparation method thereof. The hydroxycamptothecine long-circulating liposome is prepared from the following components in parts by weight: 1 part of hydroxycamptothecine, 5-30 parts of phospholipid, 1-5 parts of cholesterol, 1-20 parts of TPGS (tocopherol polyethylene glycol succinate), 1-8 parts of poloxamer188. The hydroxycamptothecine long-circulating liposome prepared by the method is proper in grain diameter, high in encapsulation, low in raw material price and simple in process, and is suitable for industrial production.

Provided herein are compositions that contain water-soluble vitamin E derivative mixtures (compositions), such as tocopheryl polyethylene glycol succinate (TPGS), TPGS analogs, TPGS homo logs and TPGS derivatives. The water-soluble vitamin E mixtures contain mixtures of dimers and monomers of the vitamin E derivative. Also provided are products containing the water-soluble vitamin E derivative mixtures, including concentrates for dilution into aqueous beverages and compositions for direct ingestion.

The invention discloses a bazedoxifene acetate composition with excellent properties. The composition comprises bazedoxifene acetate, polyethylene glycol (PEG) 6000-8000 and vitamin E tocopherol polyethylene glycol succinate (TPGS), wherein a solid solution and/or solid sol is formed by polyethylene glycol (PEG) 6000-8000 and vitamin E TPGS, and bazedoxifene acetate is dispersed into the solid solution and/or solid sol. The composition is high in chemical stability and medicine release speed.

The invention discloses anti-tumor magnetic drug-loading hybridized nanocapsules and a preparation method thereof. The preparation method comprises the following steps: firstly, preparing oleic acid coated magnetic ferroferric oxide nanoparticles (Fe3O4-OA); after modifying heparin sodium by TPGS (Tocopherol Polyethylene Glycol Succinate) and PEG (Polyethylene Glycol) through condensation reaction, carrying out an ultrasonic emulsification method to prepare Fe3O4-OA and adriamycin coated magnetic nanocapsules; then modifying the peripheries of the capsules with tumor cell-penetrating peptidesiRGD to provide a tumor cell targeting function; finally, treating through ammonium bicarbonate to form the magnetic drug-loading hybridized nanocapsules. The magnetic drug-loading hybridized nanocapsules prepared by the invention have strong targeting performance and have good stimulation response performance under the illumination of near infrared laser; carbon dioxide gas can be produced and high-selectivity rapid drug release of the nanocapsules on a tumor part is realized; meanwhile, the nanocapsules have good biocompatibility and high safety and also have certain magnetic response behaviors.

The invention discloses a preparation method of d-alpha-tocopherol polyethylene glycol succinate. The preparation method comprises the following steps: by taking Merrifield resin and PEG1,000 as raw materials and alkali as a catalyst, performing reaction at 45-135 DEG C in an organic solvent to obtain resin loaded with PEG1,000; under the action of the catalyst, enabling the resin loaded with PEG1,000 and d-alpha-tocopherol succinate to be subjected to water diversion reflux reaction to obtain resin loaded with TPGS; and soaking the resin loaded with TPGS in toluene, then adding ethanol, palladium on carbon and phosphopyridoxal, and performing stirring reaction at 100-110 DEG C for 24 hours in hydrogen gas of 0.8-1.5MPa to obtain the d-alpha-tocopherol polyethylene glycol succinate. By adopting the synthetic method disclosed by the invention, the yield of TPGS is as high as 99%, the monoester content of TPGS is 99%, and the diester content of TPGS is 0.

Proposed is a pharmaceutical composition for oral administration, the composition including an ionic bond complex composed of teriparatide, deoxycholic acid, Nα-deoxycholyl-L-lysyl-methylester (DCK), and di-alpha-tocopherol polyethylene glycol 1000 succinate, and a method for preparing the same is also proposed. The oral pharmaceutical composition is useful for the treatment of osteoporosis because the pharmaceutical composition can increase intestinal membrane permeability and oral administration bioavailability of teriparatide and improve patient compliance.